Composition for regulating platelet aggregation, screening method taking platelet-derived growth factor receptor alpha as target spot and application

Through virtual screening and physical experimental verification, the compositions of geraniol, amaranthone, uranthorin, hemelliformin and erinacein were screened out. As a composition for regulating platelet aggregation, the existing technology was solved. The lack of regulation of platelet aggregation has achieved efficient, safe and low-toxic therapeutic effects, and is suitable for the prevention and treatment of cardiovascular diseases.

CN118987008AActive Publication Date: 2024-11-22WEST ANHUI UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411092726.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The prior art is difficult to develop a novel, efficient, safe, low toxic and convenient composition for regulating platelet aggregation, especially blocking agents targeting platelet derived growth factor receptor alpha (PDGFRA) targets for treatment and prevention Cardiovascular disease.

Method used

Through virtual screening molecular docking method and combined with solid experimental verification, the composition of five traditional Chinese medicine components, geraniol, amaranthone, uranthorin, hemelliformin and erinacein, was screened as a combination of regulating platelet aggregation The composition is and its optimal ratio is determined by optimizing the ratio.

Benefits of technology

It has achieved significant regulation of platelet aggregation, has no obvious toxic side effects, no contraindications or adverse reactions, and can be used for a long time, with high accuracy, accurate and reliable results, which significantly improves the treatment and prevention effects of cardiovascular diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004987032060000052
    Figure BDA0004987032060000052
  • Figure BDA0004987032060000061
    Figure BDA0004987032060000061
  • Figure BDA0004987032060000071
    Figure BDA0004987032060000071
Patent Text Reader

Abstract

The invention relates to the technical field of traditional Chinese medicine chemistry, in particular to a composition for regulating platelet aggregation, a screening method taking a platelet-derived growth factor receptor alpha as a target spot and application, the composition can effectively inhibit platelet aggregation, experiments prove that the composition has an obvious curative effect on regulating platelet aggregation, and the composition has a good application prospect. The composition can be prepared into tablets, capsules, syrup, oral liquid, injection and the like, has the advantages of remarkable curative effect, no contraindication, no adverse reaction and the like, and can be used for a long time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of Chinese medicine chemistry, and in particular to a composition for regulating platelet aggregation, a screening method using platelet-derived growth factor receptor alpha as a target, and an application thereof. Background Art

[0002] Platelet-derived growth factor receptor α (PDGFRA) is a transmembrane single-chain glycoprotein and a tyrosine kinase receptor. It plays an important role in angiogenesis and cell division promotion. It is mainly present in cells regulated by platelet-derived growth factor, such as endothelial cells, smooth muscle cells, fibroblasts, glomerular cells, and tumor cells. It plays a role in platelet activation, platelet granule secretion agonists, and thrombin-induced platelet aggregation. PDGFRA antagonists can block the occurrence of these effects and have great application prospects. They have a protective effect on cerebral ischemia and encephalitis, and have a good therapeutic and preventive effect on PDGFRA-induced cardiovascular diseases. Therefore, it is of great significance to find and develop new, efficient, safe, low-toxic, and convenient combination compounds that have the effect of regulating platelet aggregation based on PDGFRA. Summary of the invention

[0003] In view of the deficiencies of the prior art, the present invention provides a composition for regulating platelet aggregation with platelet-derived growth factor receptor α (PDGFRA) as a target.

[0004] Another object of the present invention is to provide a method for screening the composition by virtual screening molecular docking, taking platelet-derived growth factor receptor α (PDGFRA) as a target, or combining it with physical experimental verification.

[0005] The object of the present invention is achieved in the following ways:

[0006] A composition for regulating platelet aggregation comprises the following components: geraniol, cyasterone, kakkalide, hemerocallin and formononetin.

[0007] Preferably, the platelet aggregation regulating composition comprises 2-4 parts by weight of geraniol, 0.7-1.9 parts by weight of cyasterone, 1.1-3.1 parts by weight of kakkalide, 0.7-1.3 parts by weight of hemerocallin and 0.8-1.6 parts by weight of formononetin.

[0008] The most preferred composition for regulating platelet aggregation is: 2 parts by weight of geraniol, 0.7 parts by weight of cyasterone, 1.1 parts by weight of kakkalide, 0.7 parts by weight of hemerocallin and 0.8 parts by weight of formononetin.

[0009] The method for screening the above-mentioned composition for regulating platelet aggregation using platelet-derived growth factor receptor alpha (PDGFRA) as a target comprises the following steps:

[0010] 1) Obtaining the three-dimensional structure of platelet-derived growth factor receptor α (PDGFRA) protein;

[0011] 2) Using molecular docking software, the active site region of the platelet-derived growth factor receptor α (PDGFRA) protein structure was determined with Sunitinib as the center;

[0012] 3) Computer virtual screening was performed on the small molecule ligands of five Chinese medicinal materials, namely, Bupleurum, Cyathula, Pueraria, Hemerocallis and Pueraria, and the platelet-derived growth factor receptor α (PDGFRA) protein. According to the set active site region, molecular docking software was used to perform molecular docking on each small molecule ligand and the platelet-derived growth factor receptor α (PDGFRA) active site region, and the docking score data was recorded;

[0013] 4) Sorting the docking score results of step 3) (for each Chinese medicinal material, selecting the small molecule ligand with the highest docking score) to determine the composition that can regulate platelet aggregation: geraniol, cyasterone, kakkalide, hemerocallin and formononetin.

[0014] In the above method, before obtaining the three-dimensional structure of platelet-derived growth factor receptor α (PDGFRA) protein, the effective chemical components of five Chinese medicinal materials, namely, Bupleurum chinense, Cyathula capitata, Pueraria lobata, Hemerocallis radix and Pueraria lobata, were searched from public databases, and a total of 264 chemical component information were obtained, including 83 from Bupleurum chinense, 36 from Cyathula capitata, 104 from Pueraria lobata, 24 from Hemerocallis radix and 17 from Pueraria lobata. The MacroModel small molecule ligand preprocessing optimization module was applied to each compound for preprocessing optimization.

[0015] In the above method, the MacroModel small molecule ligand pretreatment optimization module was applied to each compound for pretreatment optimization, and the energy threshold was set to 0.5 kJ·nm -1 ·mol -1 .

[0016] In step 1) of the above method, the three-dimensional structure of the platelet-derived growth factor receptor alpha (PDGFRA) protein is obtained through the RCSB PDB protein database, and its PDB ID is 5GRN. The protein has 356 amino acid residues and is constructed by X-ray diffraction (X-RAY DIFFRACTION) with a resolution of:

[0017] In step 1) of the above method, after the three-dimensional structure of the platelet-derived growth factor receptor alpha (PDGFRA) protein is obtained, the constructed protein can be model verified and the structural rationality can be evaluated by molecular dynamics.

[0018] In step 2) of the above method, the specific method for determining the active site region of the platelet-derived growth factor receptor alpha (PDGFRA) protein structure with sunitinib as the center is: the platelet-derived growth factor receptor alpha (PDGFRA) protein and sunitinib are respectively added to the molecular docking Maestro system, and hydrogen atoms are added, water molecules are deleted, and heavy atoms are processed before processing, and the receptor grid generation (i.e., active pocket generation) panel under the glide docking module is used to determine the active site region of the platelet-derived growth factor receptor alpha (PDGFRA) protein structure with sunitinib as the center.

[0019] The above method for screening a composition for regulating platelet aggregation using platelet-derived growth factor receptor α (PDGFRA) as a target specifically comprises the following steps:

[0020] 1) The effective chemical components of five Chinese medicinal materials, namely, Bupleurum chinense, Cyathula officinalis, Pueraria lobata, Hemerocallis radix and Pueraria lobata, were searched from public databases. A total of 264 chemical components were obtained, including 83 from Bupleurum chinense, 36 from Cyathula officinalis, 104 from Pueraria lobata, 24 from Hemerocallis radix and 17 from Pueraria lobata. The MacroModel small molecule ligand pretreatment optimization module was used to optimize the pretreatment of each compound.

[0021] 2) The three-dimensional structure of platelet-derived growth factor receptor α (PDGFRA) protein was obtained through the RCSB PDB protein database. Its PDB ID is 5GRN. The protein has 356 amino acid residues and is constructed using X-RAY DIFFRACTION with a resolution of:

[0022] 3) The platelet-derived growth factor receptor α (PDGFRA) protein and sunitinib obtained in step 2) were added to the molecular docking Maestro system respectively, and hydrogen atoms were added, water molecules were deleted, and heavy atoms were processed. The receptor grid generation panel under the glide docking module was used to determine the active site region of the platelet-derived growth factor receptor α (PDGFRA) protein structure with sunitinib as the center; 264 compound molecules of the four traditional Chinese medicines obtained in step 1) were introduced into the molecular docking Maestro system, and the distance between the platelet-derived growth factor receptor α (PDGFRA) protein and the compound molecules (i.e., the small molecule ligands mentioned above) was set to 1.0 / 0.8; standard accuracy was selected for accuracy, that is, 264 compound molecules of five traditional Chinese medicines, namely, Bupleurum, Cyathula, Pueraria, Hemerocallis and Pueraria, were introduced into the molecular docking Maestro system respectively. The compounds were inserted into the active site region of the platelet-derived growth factor receptor α (PDGFRA) protein structure, and virtual screening was carried out with the platelet-derived growth factor receptor α (PDGFRA) protein. Each compound was molecularly docked with the active site region of the platelet-derived growth factor receptor α (PDGFRA), and the docking score data was recorded. The compounds were sorted according to the docking scores to determine the composition that can regulate platelet aggregation: geraniol, cyasterone, kakkalide, hemerocallin and formononetin.

[0023] 4) Verify biological activity through physical pharmacology experiments.

[0024] The present invention conducts the following specific entity pharmacological experiments to verify the above method of screening a composition for regulating platelet aggregation using platelet-derived growth factor receptor α (PDGFRA) as a target:

[0025] 1) ICR mice weighing 18-22 g were given the corresponding drugs by tail vein injection for 7 consecutive days. Blood was collected from the mouse eyeballs within 1.5-2.5 hours after the last administration, and heparin sodium was used for anticoagulation. The supernatant was centrifuged to obtain drug-containing plasma;

[0026] 2) The mouse platelet-derived growth factor receptor α (PDGFRA) enzyme-linked immunosorbent assay (ELISA) kit was used to determine the mouse platelet-derived growth factor receptor α (PDGFRA) level in the sample by the double antibody sandwich method, the absorbance (OD value) was measured by an enzyme reader, and the platelet-derived growth factor receptor α (PDGFRA) concentration in the drug-containing plasma of the mouse was calculated by the standard curve;

[0027] 3) The difference between each measured value and the blank control group was divided by the measured value of the blank control group to obtain the platelet-derived growth factor receptor α (PDGFRA) inhibition rate to evaluate the pharmacodynamic characteristics of the five compound combinations of geraniol, cyasterone, kakkalide, hemerocallin and formononetin in inhibiting PDGFRA.

[0028] The composition screened by the method of the present invention can be prepared into a preparation with pharmaceutically acceptable excipients, and the dosage form can be tablets, capsules, syrups, oral liquids, injections, etc. The Chinese medicine composition of the present invention has the advantages of no obvious toxic and side effects, significant efficacy, no contraindications and adverse reactions, and can be used for a long time.

[0029] The last object of the present invention is to disclose the use of the aforementioned platelet aggregation regulating composition in the preparation of drugs for resisting platelet aggregation or regulating platelet aggregation.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] (1) The present invention screens a platelet aggregation inhibitor with geraniol, cyasterone, kakkalide, hemerocallin and formononetin as a composite. The compound is derived from traditional Chinese medicine, has no obvious toxic side effects, has significant efficacy, no contraindications and adverse reactions, and can be used for a long time.

[0032] (2) The present invention provides a method for screening a Chinese medicine composition having an anti-platelet aggregation effect by using PDGFRA as a target through a combination of a virtual screening molecular docking method and a physical experimental verification, with high precision and accurate and reliable results.

[0033] (3) The present invention firstly uses virtual screening molecular docking technology to screen the most excellent compound monomers for PDGFRA target from five Chinese medicinal materials including Bupleurum, Cyathula, Pueraria, Hemerocallis and Pueraria, and then combines and proportions the five selected monomers, which have obvious platelet aggregation regulating effects and synergistic effects. The drug ratio used in the composition of the present invention has been verified through a large number of experiments, and any drug dosage that is too low or too high will affect the efficacy of regulating platelet aggregation. DETAILED DESCRIPTION

[0034] The present invention is further explained below by way of examples:

[0035] Embodiment 1:

[0036] (1) The effective chemical components of five Chinese medicinal materials, namely, Bupleurum chinense, Cyathula officinalis, Pueraria lobata, Hemerocallis tinctorius, and Pueraria lobata, were searched from the database (TCMSP Chinese Herbal Medicine Systems Pharmacology Platform). A total of 264 chemical component information was obtained, including 83 from Bupleurum chinense (the names of the compounds included are shown in Table 1), 36 from Cyathula officinalis (the names of the compounds included are shown in Table 2), 104 from Pueraria lobata (the names of the compounds included are shown in Table 3), 24 from Hemerocallis tinctorius (the names of the compounds included are shown in Table 4), and 17 from Pueraria lobata (the names of the compounds included are shown in Table 5). The MacroModel small molecule ligand pretreatment optimization module was used to pre-process and optimize the active component database (which consists of 264 chemical component information) for each compound, and the energy threshold was set to 0.5 kJ·nm -1 ·mol -1 The MacroModel small molecule ligand pre-processing optimization module converts the two-dimensional planar structure of the compound into a three-dimensional structure and performs energy optimization pre-processing;

[0037] (2) The three-dimensional structure of PDGFRA protein was obtained through the RCSB PDB protein database. Its PDB ID is 5GRN. The protein has 356 amino acid residues and is constructed by X-ray diffraction (X-RAY DIFFRACTION) with a resolution of:

[0038] (3) The PDGFRA protein and Sunitinib obtained in step (2) were respectively introduced into the molecular docking Maestro system to add hydrogen atoms (because there are no hydrogen atoms in the protein structure, hydrogenation was performed in batches), delete water molecules, and process heavy atom-related pre-processing. The receptor grid was used under the glide docking module. generation panel, with Sunitinib as the center, determine the active site region of the PDGFRA protein structure; set the distance between the PDGFRA protein and the compound molecule to 1.0 / 0.8, select "standard accuracy" for accuracy, perform molecular docking between Sunitinib and the PDGFRA active site region, and record the total docking score. The result shows that the docking score of Sunitinib and PDGFRA is -9.0401. This score is used as the threshold to judge the effect of the five Chinese medicinal materials on PDGFRA. The 264 small molecules of the compounds obtained in step (1) are introduced into the active site region of the PDGFRA protein structure, and virtual screening is performed with the PDGFRA protein. The docking score data is recorded (the docking score data is mainly composed of the lipophilicity, hydrogen bond, metal ligand, rotation of inappropriate bonds and spatial repulsion of atoms between the small molecule compound and the PDGFRA protein. The docking score data is composed of the molecular The docking system calculated according to the built-in logic of the molecular docking system and then directly outputted it). The results showed that geraniol in Bupleurum (see Table 1 for details, docking score -9.792), cyasterone in Cyathula (see Table 2 for details, docking score -9.652), kakkalide in Pueraria lobata (see Table 3 for details, docking score -9.942), hemerocallin in Hemerocallis root (see Table 4 for details, docking score -9.663), and formononetin in Pueraria root (see Table 5 for details, docking score -9.509) had the highest score after docking with PDGFRA (i.e., the highest absolute value of the score), which was above the threshold set by Sunitinib (i.e., the absolute value of each docking score was compared with the absolute value of the docking score of Sunitinib). Therefore, geraniol, cyasterone, kakkalide, hemerocallin and formononetin were selected for the combination ratio of platelet aggregation regulating compounds.

[0039] Table 1 Virtual screening results of Bupleurum chinense and platelet-derived growth factor receptor α (PDGFRA)

[0040]

[0041]

[0042]

[0043] Table 2 Virtual screening results of Cyathula capitata and platelet-derived growth factor receptor α (PDGFRA)

[0044]

[0045]

[0046] Table 3 Results of molecular docking between Pueraria lobata and platelet-derived growth factor receptor α (PDGFRA)

[0047]

[0048]

[0049]

[0050]

[0051] Table 4 The docking results of Hemerocallis root and platelet-derived growth factor receptor α (PDGFRA) molecule

[0052]

[0053]

[0054] Table 5 Molecular docking results of Pueraria root and platelet-derived growth factor receptor α (PDGFRA)

[0055]

[0056] The method for screening a composition that can regulate platelet aggregation using PDGFRA as a target is verified by the following physical experiments:

[0057] (1) 140 ICR mice, weighing 18-22 g, were produced and distributed by Shanghai Jiesijie Experimental Animal Co., Ltd. and randomly divided into 28 groups, each with 5 mice. They were given the monomers or combinations of the five compounds geraniol, cyasterone, kakkalide, hemerocallin and formononetin corresponding to groups 1-28 in Table 6 (the types and doses of drugs given to each group are detailed in Table 6). Each drug in each group was dissolved in physiological saline according to the corresponding dose in advance and injected into the tail vein for 7 consecutive days. Within 1.5-2.5 hours after the last dose, blood was collected from the eyeballs of the ICR mice, anticoagulated with heparin sodium, and centrifuged at 5000 rpm to obtain the drug-containing plasma supernatant for later use.

[0058] Table 6 PDGFRA ELISA kit test results

[0059]

[0060]

[0061] A: geraniol; B: cyasterone; C: kakkalide; D: hemerocallin; E: formononetin. * P<0.05, compared with empty

[0062] Compared with the white control group, there was a statistically significant difference; a P < 0.05, compared with group 4 (A: 4 mg kg -1 ) compared with the control group, there was a statistically significant difference; b P < 0.05, compared with group 22 (C: 1.1 mg kg -1 ; D: 0.8 mg kg -1 ) compared with the control group, there was a statistically significant difference; c P<0.05, compared with group 25 (D: 0.7 mg kg -1 ; B: 0.7 mg kg -1 ; C: 1.1 mg kg -1 ) compared with the control group, there was a statistically significant difference. d P<0.05, compared with group 27 (A: 2 mg kg -1 ; B: 0.7 mg kg -1 ; C: 1.1 mg kg -1 ; D: 0.7 mg kg -1 ) compared with the control group, there was a statistically significant difference.

[0063] (2) The mouse platelet-derived growth factor receptor α (PDGFRA) enzyme-linked immunosorbent assay (ELISA) kit provided by Shanghai Sigma Biotechnology Co., Ltd. was used. The double antibody sandwich method was used according to the instructions to determine the mouse PDGFRA level in the sample (i.e., drug-containing plasma). The absorbance (OD value) was measured at a wavelength of 450 nm using the Synergy2 American Bio-Tech multifunctional microplate reader. The mouse PDGFRA concentration in the sample (i.e., drug-containing plasma) was calculated using the standard curve.

[0064] (3) The difference between the measured value of each drug-containing plasma and the blank control group was divided by the measured value of the blank control group to obtain the PDGFRA inhibition rate. The detailed results are shown in Table 6 (the data of 5 mice in each group together constitute the inhibition rate column in Table 6), where the measured value is the measured mouse PDGFRA concentration value in drug-containing plasma. The results showed that Group 28 (geraniol 2 mg kg -1 , cyasterone 0.7mg kg -1 kakkalide 1.1mg kg -1、hemerocallin 0.7mg kg -1 and formononetin 0.8 mg kg -1 ) were compared with the blank group, the highest value of the low, medium and high dose groups of the five single compounds (Group 4), the highest value of the two combinations of the five compounds (Group 22), the highest value of the three combinations of the five compounds (Group 25), and the highest value of the four combinations of the five compounds (Group 27), which were statistically significant, indicating that the five-compound combination of geraniol, cyasterone, kakkalide, hemerocallin and formononetin of the present invention has a good inhibition rate on PDGFRA, so the five-compound combination of geraniol, cyasterone, kakkalide, hemerocallin and formononetin can regulate platelet aggregation (manifested as inhibition).

[0065] Example 2

[0066] 2 parts by weight of geraniol, 0.7 parts by weight of cyasterone, 1.1 parts by weight of kakkalide, 0.7 parts by weight of hemerocallin and 0.8 parts by weight of formononetin;

[0067] The above components are mixed with granule auxiliary materials, and granules are prepared according to a conventional preparation method.

[0068] Example 3

[0069] 2 parts by weight of geraniol, 0.7 parts by weight of cyasterone, 1.1 parts by weight of kakkalide, 0.7 parts by weight of hemerocallin and 0.8 parts by weight of formononetin;

[0070] The above components are mixed with tablet auxiliary materials and compressed into tablets according to conventional preparation methods.

[0071] Example 4

[0072] 2 parts by weight of geraniol, 0.7 parts by weight of cyasterone, 1.1 parts by weight of kakkalide, 0.7 parts by weight of hemerocallin and 0.8 parts by weight of formononetin;

[0073] After the above components are mixed, the oral liquid is prepared according to a conventional oral liquid preparation method.

[0074] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.

Claims

1. A composition for regulating platelet aggregation, It is characterized in that The composition comprises the following components: Geraniol, cyasterone, kakkalide, hemerocallin and formononetin.

2. The composition for regulating platelet aggregation according to claim 1, It is characterized in that The composition: 2-4 parts by weight of geraniol, 0.7-1.9 parts by weight of cyasterone, 1.1-3.1 parts by weight of kakkalide, 0.7-1.3 parts by weight of hemerocallin and 0.8-1.6 parts by weight of formononetin.

3. A method for screening a composition for regulating platelet aggregation using platelet-derived growth factor receptor α as a target, It is characterized in that The following steps are involved: 1) Obtaining the three-dimensional structure of platelet-derived growth factor receptor α (PDGFRA) protein; 2) Using molecular docking software, we determined the active site region of the platelet-derived growth factor receptor α (PDGFRA) protein structure with sunitinib as the center; 3) Computer virtual screening was performed on the small molecule ligands of five Chinese medicinal materials, namely, Bupleurum chinense, Cyathula officinalis, Pueraria lobata, Hemerocallis radix and Pueraria lobata, and the platelet-derived growth factor receptor α (PDGFRA) protein. According to the set active site region, molecular docking software was used to perform molecular docking on each small molecule ligand and the platelet-derived growth factor receptor α (PDGFRA) active site region, and the docking score data was recorded; 4) According to the docking score results of step 3), the composition that can regulate platelet aggregation is determined: geraniol, cyasterone, kakkalide, hemerocallin and formononetin.

4. The method for screening a composition for regulating platelet aggregation by targeting platelet-derived growth factor receptor α according to claim 3, It is characterized in that Before obtaining the three-dimensional structure of platelet-derived growth factor receptor α (PDGFRA) protein, the effective chemical components of five traditional Chinese medicinal materials, namely Bupleurum, Cyathula, Pueraria, Hemerocallis and Pueraria, were searched from the database. A total of 264 chemical components were obtained, including 83 from Bupleurum, 36 from Cyathula, 104 from Pueraria, 24 from Hemerocallis and 17 from Pueraria. The MacroModel small molecule ligand preprocessing optimization module was applied to each compound for preprocessing optimization.

5. The method for screening a composition for regulating platelet aggregation using platelet-derived growth factor receptor α as a target according to claim 4, It is characterized in that MacroModel small molecule ligand pretreatment optimization module was applied to each compound for pretreatment optimization, and the energy threshold was set to 0.5 kJ×nm -1 ×mol -1 .

6. The method for screening a composition for regulating platelet aggregation by targeting platelet-derived growth factor receptor α according to claim 3, It is characterized in that In step 1), the three-dimensional structure of the platelet-derived growth factor receptor α (PDGFRA) protein was obtained in the following way: obtained through the RCSB PDB protein database, its PDB ID is 5GRN, the protein has a total of 356 amino acid residues, and its construction method is X-ray diffraction, with a resolution of 1.77 Å.

7. The method for screening a composition for regulating platelet aggregation by targeting platelet-derived growth factor receptor α according to claim 3, It is characterized in that The specific method for determining the active site region of the platelet-derived growth factor receptor alpha protein (PDGFRA) structure with sunitinib as the center in step 2) is as follows: the platelet-derived growth factor receptor alpha (PDGFRA) protein and sunitinib are respectively added to the molecular docking Maestro system, and hydrogen atoms are added, water molecules are deleted, and heavy atoms are processed before processing. The active pocket generation panel under the glide docking module is used to determine the active site region of the platelet-derived growth factor receptor alpha protein (PDGFRA) structure with sunitinib as the center.

8. The method for screening a composition for regulating platelet aggregation by targeting platelet-derived growth factor receptor α according to claim 3, It is characterized in that The following steps are involved: (1) The effective chemical components of five traditional Chinese medicines, namely, Bupleurum chinense, Cyathula officinalis, Pueraria lobata, Hemerocallis radix and Pueraria lobata, were searched from the database. A total of 264 chemical components were obtained, including 83 from Bupleurum chinense, 36 from Cyathula officinalis, 104 from Pueraria lobata, 24 from Hemerocallis radix and 17 from Pueraria lobata. The MacroModel small molecule ligand pretreatment optimization module was used to optimize the pretreatment of each compound. (2) The structure of platelet-derived growth factor receptor α (PDGFRA) protein was obtained through the RCSB PDB protein database. Its PDB ID is 5GRN. The protein has 356 amino acid residues and was constructed by X-ray diffraction with a resolution of 1.77Å. (3) The platelet-derived growth factor receptor α protein and sunitinib obtained in step (2) were added to the molecular docking Maestro system respectively, and hydrogen atoms were added, water molecules were deleted, and heavy atoms were processed. The active pocket generation panel under the glide docking module was used to determine the active site region of the platelet-derived growth factor receptor α (PDGFRA) protein structure with sunitinib as the center; 264 compound molecules of the five traditional Chinese medicines obtained in step (1) were introduced into the molecular docking Maestro system , the distance between the platelet-derived growth factor receptor α (PDGFRA) protein and the compound molecules was set to 1.0 / 0.8; that is, 264 compound molecules from five Chinese medicinal materials, namely, Bupleurum, Cyathula, Pueraria, Hemerocallis and Pueraria, were introduced into the active site region of the platelet-derived growth factor receptor α (PDGFRA) protein structure, and virtual screening was performed with the platelet-derived growth factor receptor α (PDGFRA) protein. Each compound was molecularly docked with the active site region of the platelet-derived growth factor receptor α (PDGFRA), and the docking score data was recorded; The docking scores were ranked and the combination that can regulate platelet aggregation was identified: geraniol, cyasterone, kakkalide, hemerocallin and formononetin; (4) Verify biological activity through physical pharmacology experiments.

9. The method for screening a composition for regulating platelet aggregation by targeting platelet-derived growth factor receptor α according to claim 8, It is characterized in that The pharmacological experimental steps are as follows: (1) ICR mice weighing 18-22 g were given the corresponding drugs by tail vein injection for 7 consecutive days. Blood was collected from the mouse eyeballs within 1.5-2.5 hours after the last administration, and anticoagulated with heparin sodium. The supernatant was centrifuged to obtain drug-containing plasma; (2) The mouse PDGFRA enzyme-linked immunosorbent assay kit was used to determine the level of mouse platelet-derived growth factor receptor (PDGFRA) in the specimen using the double antibody sandwich method. The absorbance was measured using an enzyme-labeled instrument, and the concentration of platelet-derived growth factor receptor α (PDGFRA) in the drug-containing plasma of the mouse was calculated using the standard curve. (3) The difference between each measured value and the blank control group was divided by the measured value of the blank control group to obtain the platelet-derived growth factor receptor α (PDGFRA) inhibition rate, so as to evaluate the pharmacodynamic characteristics of the five compound combinations in inhibiting platelet-derived growth factor receptor α (PDGFRA).

10. Use of the platelet aggregation regulating composition according to claim 1 or 2 in the preparation of drugs for resisting platelet aggregation or regulating platelet aggregation.

Citation Information

Patent Citations

  • Application of formononetin in preparation of medicine capable of treating hypertension and ischemic angiocardiopathy and cerebrovascular disease

    CN101596185A

  • Pharmaceutical composition for improving platelet aggregation, and pharmaceutical composition screening method adopting PTAFR as target point

    CN104983738A

  • Application of cycloastragenol and composition in preparation of antiplatelet and antithrombotic drugs

    CN115645418A

  • Antithrombotic drug

    JP1986194017A